{"created":"2023-07-27T06:38:41.366249+00:00","id":26842,"links":{},"metadata":{"_buckets":{"deposit":"95ef4460-36ff-4ef7-97c0-29c99e127c2b"},"_deposit":{"created_by":3,"id":"26842","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"26842"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00026842","sets":["1761:1762:1763"]},"author_link":["330","118","504"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-02-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"10","bibliographicPageStart":"2","bibliographicVolumeNumber":"36","bibliographic_titles":[{"bibliographic_title":"日本臨床免疫学会会誌 = Japanese journal of clinical immunology"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"慢性腎臓病から末期腎不全に至り，維持透析を必要としている患者は依然として減少しない．慢性腎臓病の進展機序を考えるとき，慢性炎症から線維化へ至る過程において，炎症促進系因子，免疫抑制系因子が複雑に関与しながら病態を形成しているものと考えられる．それらの因子の中で，骨髄由来細胞に着目すると，これまでの多くの報告が，炎症性マクロファージ（Mφ）をはじめとする炎症促進系細胞に関するものであった．近年，Mφの分画に，炎症促進系（M1）のほかに，免疫抑制系（M2）の分画が存在することが明らかとなり，種々の臓器において炎症の抑制，組織の修復に関与していることが報告されている．また新たな細胞分画であるMyeloid derived suppressor cell（MDSC）も同定され，その免疫抑制能に関しても検討がなされている．本稿では，これら免疫抑制性細胞の進行性腎障害における意義について，概説する． Immunosuppressive cells have been reported to contribute to the inflammatory diseases in various organs. Interferon (IFN)-γ stimulations skew macrophages (Mφ) toward classically activated (M1) phenotype and interleukin (IL)-4, IL-13, IL-10 skew toward alternatively activated (M2) phenotypes. M2 polarized Mφhas immune regulatory function via various mechanisms, such as cytokine/chemokine expression, high activity of scavenging and interaction with other type of cells. Recently, another type of immunosuppressive myeloid cells, myeloid derived suppressor cells (MDSC), have been explored not only in tumor immunology, but also in inflammatory diseases. Orchestration of inflammation by these immunosuppressive cells with inflammatory cells has impact on progressive kidney diseases as well as inflammatory diseases.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本臨床免疫学会 = Japanese Society for Clinical Immunology"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2177/jsci.36.2","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://jsci.imic.or.jp/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/article/jsci/36/1/36_2/_article","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://japanlinkcenter.org/DN/JST.JSTAGE/jsci/36.2","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2013 日本臨床免疫学会"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00357971","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0911-4300","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岩田, 恭宜"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"古市, 賢吾"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"和田, 隆志"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"ME-PR-IWATA-Y-2.pdf","filesize":[{"value":"631.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-IWATA-Y-2.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/26842/files/ME-PR-IWATA-Y-2.pdf"},"version_id":"fe4fae53-86e3-4234-a7bb-97cdffa7003b"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"進行性腎疾患における骨髄由来免疫抑制性細胞の意義","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"進行性腎疾患における骨髄由来免疫抑制性細胞の意義"},{"subitem_title":"Involvement of myeloid derived immunosuppressive cells in progressive renal diseases","subitem_title_language":"en"}]},"item_type_id":"4","owner":"3","path":["1763"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"26842","relation_version_is_last":true,"title":["進行性腎疾患における骨髄由来免疫抑制性細胞の意義"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-27T21:17:52.202744+00:00"}